Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations

Background: The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoint...

Celý popis

Podrobná bibliografie

Hlavní autoři:	J. Ros, V. Navarro, G. Villacampa, I. Baraibar, F. Salvà, M. Rodriguez, C. Vaghi, A. Garcia, A. Alcaraz, J. Tabernero, E. Élez, R. Dienstmann
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-09-01
Edice:	ESMO Gastrointestinal Oncology
Témata:	surrogate markers BRAF mutation colorectal cancer targeted therapy BRAF inhibitor
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2949819825000949
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!